Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Levodopa-induced ocular dyskinesias in Parkinson's disease

Identifieur interne : 002823 ( PascalFrancis/Corpus ); précédent : 002822; suivant : 002824

Levodopa-induced ocular dyskinesias in Parkinson's disease

Auteurs : Gurutz Linazasoro ; Nadege Van Blercom ; Asier Lasa

Source :

RBID : Pascal:02-0206614

Descripteurs français

English descriptors

Abstract

Levodopa-induced ocular dyskinesias are very uncommon. Usually they occur simultaneously with limb peak-dose choreatic dyskinesias. We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 17
A06       @2 1
A08 01  1  ENG  @1 Levodopa-induced ocular dyskinesias in Parkinson's disease
A11 01  1    @1 LINAZASORO (Gurutz)
A11 02  1    @1 VAN BLERCOM (Nadege)
A11 03  1    @1 LASA (Asier)
A14 01      @1 Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián @3 ESP @Z 1 aut. @Z 2 aut. @Z 3 aut.
A20       @1 186-187
A21       @1 2002
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000100147290300
A44       @0 0000 @1 © 2002 INIST-CNRS. All rights reserved.
A45       @0 23 ref.
A47 01  1    @0 02-0206614
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 Levodopa-induced ocular dyskinesias are very uncommon. Usually they occur simultaneously with limb peak-dose choreatic dyskinesias. We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.
C02 01  X    @0 002B02U01
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Dyskinésie @5 04
C03 02  X  ENG  @0 Dyskinesia @5 04
C03 02  X  SPA  @0 Disquinesia @5 04
C03 03  X  FRE  @0 Regard @5 05
C03 03  X  ENG  @0 Gaze @5 05
C03 03  X  SPA  @0 Mirada @5 05
C03 04  X  FRE  @0 Lévodopa @2 NK @2 FR @5 07
C03 04  X  ENG  @0 Levodopa @2 NK @2 FR @5 07
C03 04  X  SPA  @0 Levodopa @2 NK @2 FR @5 07
C03 05  X  FRE  @0 Chimiothérapie @5 08
C03 05  X  ENG  @0 Chemotherapy @5 08
C03 05  X  SPA  @0 Quimioterapia @5 08
C03 06  X  FRE  @0 Antiparkinsonien @5 09
C03 06  X  ENG  @0 Antiparkinson agent @5 09
C03 06  X  SPA  @0 Antiparkinsoniano @5 09
C03 07  X  FRE  @0 Pathogénie @5 16
C03 07  X  ENG  @0 Pathogenesis @5 16
C03 07  X  SPA  @0 Patogenia @5 16
C03 08  X  FRE  @0 Etude cas @5 17
C03 08  X  ENG  @0 Case study @5 17
C03 08  X  SPA  @0 Estudio caso @5 17
C03 09  X  FRE  @0 Traitement @5 18
C03 09  X  ENG  @0 Treatment @5 18
C03 09  X  SPA  @0 Tratamiento @5 18
C03 10  X  FRE  @0 Toxicité @5 19
C03 10  X  ENG  @0 Toxicity @5 19
C03 10  X  SPA  @0 Toxicidad @5 19
C03 11  X  FRE  @0 Adulte @5 20
C03 11  X  ENG  @0 Adult @5 20
C03 11  X  SPA  @0 Adulto @5 20
C03 12  X  FRE  @0 Mâle @5 21
C03 12  X  ENG  @0 Male @5 21
C03 12  X  SPA  @0 Macho @5 21
C07 01  X  FRE  @0 Homme
C07 01  X  ENG  @0 Human
C07 01  X  SPA  @0 Hombre
C07 02  X  FRE  @0 Système nerveux pathologie @5 37
C07 02  X  ENG  @0 Nervous system diseases @5 37
C07 02  X  SPA  @0 Sistema nervioso patología @5 37
C07 03  X  FRE  @0 Système nerveux central pathologie @5 38
C07 03  X  ENG  @0 Central nervous system disease @5 38
C07 03  X  SPA  @0 Sistema nervosio central patología @5 38
C07 04  X  FRE  @0 Encéphale pathologie @5 39
C07 04  X  ENG  @0 Cerebral disorder @5 39
C07 04  X  SPA  @0 Encéfalo patología @5 39
C07 05  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 05  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 05  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 06  X  FRE  @0 Maladie dégénérative @5 41
C07 06  X  ENG  @0 Degenerative disease @5 41
C07 06  X  SPA  @0 Enfermedad degenerativa @5 41
C07 07  X  FRE  @0 Mouvement involontaire @5 45
C07 07  X  ENG  @0 Involuntary movement @5 45
C07 07  X  SPA  @0 Movimiento involuntario @5 45
C07 08  X  FRE  @0 Trouble neurologique @5 46
C07 08  X  ENG  @0 Neurological disorder @5 46
C07 08  X  SPA  @0 Trastorno neurológico @5 46
C07 09  X  FRE  @0 Oeil pathologie @5 47
C07 09  X  ENG  @0 Eye disease @5 47
C07 09  X  SPA  @0 Ojo patología @5 47
C07 10  X  FRE  @0 Oculomotricité syndrome @5 48
C07 10  X  ENG  @0 Oculomotor syndrome @5 48
C07 10  X  SPA  @0 Oculomotricidad síndrome @5 48
N21       @1 119
N82       @1 PSI

Format Inist (serveur)

NO : PASCAL 02-0206614 INIST
ET : Levodopa-induced ocular dyskinesias in Parkinson's disease
AU : LINAZASORO (Gurutz); VAN BLERCOM (Nadege); LASA (Asier)
AF : Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián/Espagne (1 aut., 2 aut., 3 aut.)
DT : Publication en série; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 186-187; Bibl. 23 ref.
LA : Anglais
EA : Levodopa-induced ocular dyskinesias are very uncommon. Usually they occur simultaneously with limb peak-dose choreatic dyskinesias. We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.
CC : 002B02U01
FD : Parkinson maladie; Dyskinésie; Regard; Lévodopa; Chimiothérapie; Antiparkinsonien; Pathogénie; Etude cas; Traitement; Toxicité; Adulte; Mâle
FG : Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Mouvement involontaire; Trouble neurologique; Oeil pathologie; Oculomotricité syndrome
ED : Parkinson disease; Dyskinesia; Gaze; Levodopa; Chemotherapy; Antiparkinson agent; Pathogenesis; Case study; Treatment; Toxicity; Adult; Male
EG : Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Involuntary movement; Neurological disorder; Eye disease; Oculomotor syndrome
SD : Parkinson enfermedad; Disquinesia; Mirada; Levodopa; Quimioterapia; Antiparkinsoniano; Patogenia; Estudio caso; Tratamiento; Toxicidad; Adulto; Macho
LO : INIST-20953.354000100147290300
ID : 02-0206614

Links to Exploration step

Pascal:02-0206614

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Levodopa-induced ocular dyskinesias in Parkinson's disease</title>
<author>
<name sortKey="Linazasoro, Gurutz" sort="Linazasoro, Gurutz" uniqKey="Linazasoro G" first="Gurutz" last="Linazasoro">Gurutz Linazasoro</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Van Blercom, Nadege" sort="Van Blercom, Nadege" uniqKey="Van Blercom N" first="Nadege" last="Van Blercom">Nadege Van Blercom</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Lasa, Asier" sort="Lasa, Asier" uniqKey="Lasa A" first="Asier" last="Lasa">Asier Lasa</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">02-0206614</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0206614 INIST</idno>
<idno type="RBID">Pascal:02-0206614</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002823</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Levodopa-induced ocular dyskinesias in Parkinson's disease</title>
<author>
<name sortKey="Linazasoro, Gurutz" sort="Linazasoro, Gurutz" uniqKey="Linazasoro G" first="Gurutz" last="Linazasoro">Gurutz Linazasoro</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Van Blercom, Nadege" sort="Van Blercom, Nadege" uniqKey="Van Blercom N" first="Nadege" last="Van Blercom">Nadege Van Blercom</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Lasa, Asier" sort="Lasa, Asier" uniqKey="Lasa A" first="Asier" last="Lasa">Asier Lasa</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Antiparkinson agent</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Gaze</term>
<term>Levodopa</term>
<term>Male</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Regard</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Pathogénie</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Adulte</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Levodopa-induced ocular dyskinesias are very uncommon. Usually they occur simultaneously with limb peak-dose choreatic dyskinesias. We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>17</s2>
</fA05>
<fA06>
<s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Levodopa-induced ocular dyskinesias in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>LINAZASORO (Gurutz)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>VAN BLERCOM (Nadege)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>LASA (Asier)</s1>
</fA11>
<fA14 i1="01">
<s1>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián</s1>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>186-187</s1>
</fA20>
<fA21>
<s1>2002</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000100147290300</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>02-0206614</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Levodopa-induced ocular dyskinesias are very uncommon. Usually they occur simultaneously with limb peak-dose choreatic dyskinesias. We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Regard</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Gaze</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Mirada</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Pathogénie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Pathogenesis</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Patogenia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Etude cas</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Case study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Estudio caso</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Toxicité</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Toxicity</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Toxicidad</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Mâle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Male</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Macho</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Mouvement involontaire</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Involuntary movement</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Movimiento involuntario</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Oeil pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Eye disease</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Ojo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Oculomotricité syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Oculomotor syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Oculomotricidad síndrome</s0>
<s5>48</s5>
</fC07>
<fN21>
<s1>119</s1>
</fN21>
<fN82>
<s1>PSI</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 02-0206614 INIST</NO>
<ET>Levodopa-induced ocular dyskinesias in Parkinson's disease</ET>
<AU>LINAZASORO (Gurutz); VAN BLERCOM (Nadege); LASA (Asier)</AU>
<AF>Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián/Espagne (1 aut., 2 aut., 3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 186-187; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>Levodopa-induced ocular dyskinesias are very uncommon. Usually they occur simultaneously with limb peak-dose choreatic dyskinesias. We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.</EA>
<CC>002B02U01</CC>
<FD>Parkinson maladie; Dyskinésie; Regard; Lévodopa; Chimiothérapie; Antiparkinsonien; Pathogénie; Etude cas; Traitement; Toxicité; Adulte; Mâle</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Mouvement involontaire; Trouble neurologique; Oeil pathologie; Oculomotricité syndrome</FG>
<ED>Parkinson disease; Dyskinesia; Gaze; Levodopa; Chemotherapy; Antiparkinson agent; Pathogenesis; Case study; Treatment; Toxicity; Adult; Male</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Involuntary movement; Neurological disorder; Eye disease; Oculomotor syndrome</EG>
<SD>Parkinson enfermedad; Disquinesia; Mirada; Levodopa; Quimioterapia; Antiparkinsoniano; Patogenia; Estudio caso; Tratamiento; Toxicidad; Adulto; Macho</SD>
<LO>INIST-20953.354000100147290300</LO>
<ID>02-0206614</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002823 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002823 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0206614
   |texte=   Levodopa-induced ocular dyskinesias in Parkinson's disease
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024